Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03029988 · ClinicalTrials.gov registry record · Phase 1
An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.
A Phase 1 study, sponsored by Navidea Biopharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT03029988: Clinical Trial Phase 1 study, sponsored by Navidea Biopharmaceuticals.
NCT03029988 is a Phase 1 study that was terminated before completion, run by Navidea Biopharmaceuticals. The registered enrollment target is 3 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03029988, a Phase 1 study, was terminated before completion, sponsored by Navidea Biopharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
Primary Outcome
The primary objectives of this study were to estimate the concordance of Tc 99m tilmanocept localization in liver metastases from colorectal carcinoma (CRC) using single photon emission computed tomography / computed tomography (SPECT/CT) imaging and abdominal fluorodeoxyglucose positron emission tomography-computed tomography (FDG PET/CT) imaging per subject and to evaluate the safety including monitoring the incidence of adverse events and changes over time in laboratory tests, vital signs, an
Interventions
- DRUG Tilmanocept (Technetium Tc 99m tilmanocept Injection)
- PROCEDURE SPECT/CT Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-07-26 |
| Est. Completion | 2018-09-24 |
| Phase | Phase 1 |
Why NCT03029988 stopped before completion
NCT03029988 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Tilmanocept (Technetium Tc 99m tilmanocept Injection) is the first listed.
NCT03029988 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03029988 about?
NCT03029988 is a clinical study titled "An Evaluation of Tilmanocept by IV Injection Using SPECT/CT vs PET Imaging in Subjects With Liver Metastases.". Estimation of the concordance of Tc 99m localization in liver metastases from colorectal carcinoma using SPECT/CT imaging and abdominal FDG (PET)/CT imaging per subject.
What is the current status of trial NCT03029988?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2017-07-26. Estimated completion is 2018-09-24.
What interventions are being tested in trial NCT03029988?
The interventions under investigation include: Tilmanocept (Technetium Tc 99m tilmanocept Injection) (DRUG), SPECT/CT Imaging (PROCEDURE).
Who is sponsoring clinical trial NCT03029988?
This trial is sponsored by Navidea Biopharmaceuticals, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03029988's enrollment target sits among peer trials
3 1999th of 2000 higher than 1 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI